A Phase 1 Study of VG-3927 in Healthy Adults and Patients With Alzheimer's Disease

Summary

A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study in Healthy Adults and Open-label Single Dose Study in Patients with Alzheimer's Disease to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VG-3927.

Timeline

Start

2023-09-22

Primary completion

2025-01-10

Completion

2025-01-10

Drugs

Indications